BlueMountain Capital says ISS supports director nominees for Taro board

BlueMountain Capital announced that Institutional Shareholder Services recommends that shareholders of Taro Pharmaceutical vote FOR the BlueMountain nominees at the company's September 12 annual general meeting. ISS also recommended that Taro shareholders vote AGAINST the approval and ratification of Taro's director and executive compensation proposals. BlueMountain together with its affiliates, which represent in excess of 1% of the voting shares and 1.5% of the total shares outstanding, is seeking to elect two new independent, external directors to Taro's board.